Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-B]pyridin-5-yl) methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide and P-glycoprotein by valspodar in gene transfectant systems

被引:0
|
作者
Kawahara, I
Kato, Y
Suzuki, H
Achira, M
Ito, K
Crespi, CL
Sugiyama, Y
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Gentest Corp, Woburn, MA USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Our previous report showed that L754.394 and valspodar (PSC833) are potent inhibitors of midazolam hydroxylation in human jejunum microsomes and vectorial transport of vinblastine in Caco-2 cells, respectively. In the present study, to directly examine the interactions of these compounds as well as other substrates with CYP3A4 and P-glycoprotein (P-gp), we performed in vitro inhibition studies using recombinant CYP3A4-expressed microsomes and an MDR1-transfected cell line, LLC-MDR1, respectively. In CYP3A4-expressed microsomes, both L754.394 and ketoconazole, at a concentration less than 0.5 mu M, are the most potent inhibitors of the formation of 1'-hydroxymidazolam, a major metabolite of midazolam formed by CYP3A4. The greatest inhibitory effect on the transcellular transport of digoxin in LLC-MDR1 cells was observed in the presence of valspodar (< 0.1 mu M), followed by verapamil. From a comparison of the IC50 values, it was shown that L754.394 and valspodar exhibited the highest selectivity for CYP3A4 and P-gp, respectively. To demonstrate such specificity, both midazolam hydroxylation and digoxin transport were observed in CYP3A4 transfected Caco-2 cells, which coexpress both P-gp and CYP3A4, in the presence or absence of L754.394 (0.5 mu M) and valspodar (1.0 mu M). L754.394 almost completely inhibited midazolam hydroxylation, but not digoxin transport, whereas almost complete inhibition of digoxin transport was observed in the presence of valspodar, but inhibition of the hydroxylation was minimal. Thus, the present study has demonstrated that L754.394 has a specific inhibitory effect on CYP3A4, whereas valspodar is specific for P-gp.
引用
收藏
页码:1238 / 1243
页数:6
相关论文
共 50 条
  • [1] N-[(R)-(6-Bromo-2-methoxyquinolin-3-yl)(phenyl)methyl]-N-[(S)-1-(4-methoxyphenyl)ethyl]-2-(piperazin-1-yl)acetamide
    Yuan, Lei
    Wang, Rui
    Li, Chang-Yi
    Wang, Zhi-Qiang
    Sun, Tie-Min
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2011, 67 : O2921 - U365
  • [2] (2S)-1-(4-Bromophenyl)-2-hydroxy-2-[(2S,5R)-5-(1-hydroxy-1-methylethyl)-tetrahydrofuran-2-yl]ethanone
    Coles, SJ
    Hursthouse, MB
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2001, 57 : O1061 - O1062
  • [3] (2S)-1-(4-fluorophenyl)-2-hydroxy-2-[(2S,5R)-5-(1-hydroxy-1-methylethyl)-tetrahydrofuran-2-yl]ethanone
    Light, ME
    Hursthouse, MB
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2001, 57 : O1196 - O1197
  • [4] (1R,2R,6S)-2(4-(4-Isopropylbenzyl)piperazin-1-yl)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-enol
    Podturkina, Alexandra V.
    Li-Zhulanov, Nikolai S.
    Volcho, Konstantin P.
    Salakhutdinov, Nariman F.
    MOLBANK, 2023, 2023 (01)
  • [5] Synthesis and Crystal Structure of (2S,2'S,4'R)-2-(1-Hydroxy-1-ethylpropyl)-1-[(1'-p-tosyl-4'-hydroxypyrrolidin-2'-yl)methyl]pyrrolidine
    FU YuQin DING LiNa ZHANG ShengHong TAO JingChao ZHU Yu Department of Chemistry New Drug Research Development Center Zhengzhou University Zhengzhou China
    结构化学, 2006, (10) : 1203 - 1208
  • [6] Synthesis and Crystal Structure of (2S,2'S,4'R)-2-(1-Hydroxy-1-ethylpropyl)-1-[(1'-p-tosyl-4'-hydroxypyrrolidin-2'-yl)methyl]pyrrolidine
    FU Yu-Qin DING Li-Na ZHANG Sheng-Hong TAO Jing-Chao ② ZHU Yu (Department of Chemistry
    Chinese Journal of Structural Chemistry, 2006, (10) : 1203 - 1208
  • [7] Synthesis and crystal structure of (2S,2′S,4′R)-2-(1-hydroxy-1-ethylpropyl)-1-[(1′-p-tosyl-4′-hydroxypyrrolidin-2′-yl)methyl]pyrrolidine
    Fu Yu-Qin
    Ding Li-Na
    Zhang Sheng-Hong
    Tao Jing-Chao
    Zhu Yu
    CHINESE JOURNAL OF STRUCTURAL CHEMISTRY, 2006, 25 (10) : 1203 - 1208
  • [8] Design and synthesis of a novel family of triazine-based inhibitors of sorbitol dehydrogenase with oral activity:: 1-{4-[3R,5S-dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(R) ethanol
    Mylari, BL
    Withbroe, GJ
    Beebe, DA
    Brackett, NS
    Conn, EL
    Coutcher, JB
    Oates, PJ
    Zembrowski, WJ
    BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (19) : 4179 - 4188
  • [9] (+)-(Z)-(1S,2S,3S,4R,1′S,2′S,3′S,4′R,5′R)-2,3,4-trihydroxy-5-(hydroxymethyl)-N-[2′,3′,4′-trihydroxy-5′-(hydroxymethyl)cyclohex-1′-yl]cyclohex-5-en-1-aminium chloride dihydrate
    Chang, HJ
    Feng, XL
    Zhu, JR
    Ng, SW
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2005, 61 : O3839 - O3841
  • [10] Synthesis and characterization of tritium labeled N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-sulfamoylbenzamide
    Hong, Yang
    Hynes, John
    Tian, Yuan
    Balasubramanian, Balu
    Bonacorsi, Samuel, Jr.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2015, 58 (10): : 414 - 418